Cargando…
Advances in TRP channel drug discovery: from target validation to clinical studies
Transient receptor potential (TRP) channels are multifunctional signalling molecules with many roles in sensory perception and cellular physiology. Therefore, it is not surprising that TRP channels have been implicated in numerous diseases, including hereditary disorders caused by defects in genes e...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442523/ https://www.ncbi.nlm.nih.gov/pubmed/34526696 http://dx.doi.org/10.1038/s41573-021-00268-4 |
_version_ | 1783753024921927680 |
---|---|
author | Koivisto, Ari-Pekka Belvisi, Maria G. Gaudet, Rachelle Szallasi, Arpad |
author_facet | Koivisto, Ari-Pekka Belvisi, Maria G. Gaudet, Rachelle Szallasi, Arpad |
author_sort | Koivisto, Ari-Pekka |
collection | PubMed |
description | Transient receptor potential (TRP) channels are multifunctional signalling molecules with many roles in sensory perception and cellular physiology. Therefore, it is not surprising that TRP channels have been implicated in numerous diseases, including hereditary disorders caused by defects in genes encoding TRP channels (TRP channelopathies). Most TRP channels are located at the cell surface, which makes them generally accessible drug targets. Early drug discovery efforts to target TRP channels focused on pain, but as our knowledge of TRP channels and their role in health and disease has grown, these efforts have expanded into new clinical indications, ranging from respiratory disorders through neurological and psychiatric diseases to diabetes and cancer. In this Review, we discuss recent findings in TRP channel structural biology that can affect both drug development and clinical indications. We also discuss the clinical promise of novel TRP channel modulators, aimed at both established and emerging targets. Last, we address the challenges that these compounds may face in clinical practice, including the need for carefully targeted approaches to minimize potential side-effects due to the multifunctional roles of TRP channels. |
format | Online Article Text |
id | pubmed-8442523 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-84425232021-09-15 Advances in TRP channel drug discovery: from target validation to clinical studies Koivisto, Ari-Pekka Belvisi, Maria G. Gaudet, Rachelle Szallasi, Arpad Nat Rev Drug Discov Review Article Transient receptor potential (TRP) channels are multifunctional signalling molecules with many roles in sensory perception and cellular physiology. Therefore, it is not surprising that TRP channels have been implicated in numerous diseases, including hereditary disorders caused by defects in genes encoding TRP channels (TRP channelopathies). Most TRP channels are located at the cell surface, which makes them generally accessible drug targets. Early drug discovery efforts to target TRP channels focused on pain, but as our knowledge of TRP channels and their role in health and disease has grown, these efforts have expanded into new clinical indications, ranging from respiratory disorders through neurological and psychiatric diseases to diabetes and cancer. In this Review, we discuss recent findings in TRP channel structural biology that can affect both drug development and clinical indications. We also discuss the clinical promise of novel TRP channel modulators, aimed at both established and emerging targets. Last, we address the challenges that these compounds may face in clinical practice, including the need for carefully targeted approaches to minimize potential side-effects due to the multifunctional roles of TRP channels. Nature Publishing Group UK 2021-09-15 2022 /pmc/articles/PMC8442523/ /pubmed/34526696 http://dx.doi.org/10.1038/s41573-021-00268-4 Text en © Springer Nature Limited 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article Koivisto, Ari-Pekka Belvisi, Maria G. Gaudet, Rachelle Szallasi, Arpad Advances in TRP channel drug discovery: from target validation to clinical studies |
title | Advances in TRP channel drug discovery: from target validation to clinical studies |
title_full | Advances in TRP channel drug discovery: from target validation to clinical studies |
title_fullStr | Advances in TRP channel drug discovery: from target validation to clinical studies |
title_full_unstemmed | Advances in TRP channel drug discovery: from target validation to clinical studies |
title_short | Advances in TRP channel drug discovery: from target validation to clinical studies |
title_sort | advances in trp channel drug discovery: from target validation to clinical studies |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442523/ https://www.ncbi.nlm.nih.gov/pubmed/34526696 http://dx.doi.org/10.1038/s41573-021-00268-4 |
work_keys_str_mv | AT koivistoaripekka advancesintrpchanneldrugdiscoveryfromtargetvalidationtoclinicalstudies AT belvisimariag advancesintrpchanneldrugdiscoveryfromtargetvalidationtoclinicalstudies AT gaudetrachelle advancesintrpchanneldrugdiscoveryfromtargetvalidationtoclinicalstudies AT szallasiarpad advancesintrpchanneldrugdiscoveryfromtargetvalidationtoclinicalstudies |